abs17.txt	lack	of	information	on	the	clinical	utility	preemptive	dpyd	screening	prior	tofluoropyrimidine	treatment	is	a	major	barrier	preventing	its	utilization	inclinical	practice		this	study	aimed	to	define	association	between	dpydvariants	and	fluoropyrimidine-related	toxicity	management	costs	cost	analysiswas	conducted	toxicities	experienced	by	550	colorectal	cancer	patientstreated	with	fluoropyrimidine-based	chemotherapy	genotyping	for	dpyd*2a	dpyd*13	dpydc	2846a>t	dpyd-hapb3	ugt1a1*28	was	done	retrospectively	anddid	not	affect	patients'	treatments	carriers	at	least	one	variantexperienced	higher	(2	972€	95%ci	2	456-3	505)	thannoncarriers	(825€	785-864)	(p<0	0001)	had	risk	toxicityrequiring	hospitalization	(or=4	14	1	87-9	14)	in	patients	receivingfluoropyrimidine/irinotecan	incremental	variant	andugt1a1*28/*28	noncarriers	975€	suggests	that	thetoxicity	during	therapy	are	associatedwith	variants	supports	thisarticle	protected	copyright	all	rights	reserved
